Laura R Steeples1, Paul Spry1, Richard W J Lee1,2,3, Ester Carreño4. 1. Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK. 2. Faculty of Medicine and Dentistry, School of Clinical Sciences, University of Bristol, Bristol, UK. 3. National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. 4. Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK. Ester.Carreno-Salas@UHBristol.nhs.uk.
Abstract
PURPOSE: To report the clinical outcomes of adalimumab therapy in cases of birdshot chorioretinitis (BCR) with cystoid macular edema (CME) refractory to conventional immunotherapy. METHODS: This is a retrospective case series of three BCR patients treated with adalimumab for refractory CME. The main outcome measure was central subfield thickness (CST) on optical coherence tomography. Any patients treated with local steroids and/or receiving systemic steroids higher than 40 mg prednisolone daily during adalimumab therapy were excluded. RESULTS: At baseline, all patients were receiving systemic corticosteroids and two second-line immunosuppressive agents. The mean duration of treatment with adalimumab was 31.2 months (range 17.2-52). The mean CST was 327 ± 112.7 μm (mean ± SD) at baseline and 256.2 ± 39.7 μm at 6 months and 235.5 ± 32.5 μm at 12 months. Adalimumab permitted cessation or reduction in the daily dose of oral prednisolone plus withdrawal of a second-line agent in all patients. CONCLUSIONS: In these patients, adalimumab was effective in the treatment of refractory CME.
PURPOSE: To report the clinical outcomes of adalimumab therapy in cases of birdshot chorioretinitis (BCR) with cystoid macular edema (CME) refractory to conventional immunotherapy. METHODS: This is a retrospective case series of three BCR patients treated with adalimumab for refractory CME. The main outcome measure was central subfield thickness (CST) on optical coherence tomography. Any patients treated with local steroids and/or receiving systemic steroids higher than 40 mg prednisolone daily during adalimumab therapy were excluded. RESULTS: At baseline, all patients were receiving systemic corticosteroids and two second-line immunosuppressive agents. The mean duration of treatment with adalimumab was 31.2 months (range 17.2-52). The mean CST was 327 ± 112.7 μm (mean ± SD) at baseline and 256.2 ± 39.7 μm at 6 months and 235.5 ± 32.5 μm at 12 months. Adalimumab permitted cessation or reduction in the daily dose of oral prednisolone plus withdrawal of a second-line agent in all patients. CONCLUSIONS: In these patients, adalimumab was effective in the treatment of refractory CME.
Authors: Glenn J Jaffe; Andrew D Dick; Antoine P Brézin; Quan Dong Nguyen; Jennifer E Thorne; Philippe Kestelyn; Talin Barisani-Asenbauer; Pablo Franco; Arnd Heiligenhaus; David Scales; David S Chu; Anne Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Eric B Suhler Journal: N Engl J Med Date: 2016-09-08 Impact factor: 91.245
Authors: Kayur H Shah; Ralph D Levinson; Fei Yu; Raquel Goldhardt; Lynn K Gordon; Christine R Gonzales; John R Heckenlively; Peter J Kappel; Gary N Holland Journal: Surv Ophthalmol Date: 2005 Nov-Dec Impact factor: 6.048
Authors: Dominique Monnet; Ralph D Levinson; Gary N Holland; Lamine Haddad; Fei Yu; Antoine P Brézin Journal: Am J Ophthalmol Date: 2007-10-18 Impact factor: 5.258
Authors: Simon R J Taylor; Susan L Lightman; Elizabeth A Sugar; Glen J Jaffe; William R Freeman; Michael M Altaweel; Igor Kozak; Janet T Holbrook; Douglas A Jabs; John H Kempen Journal: Ocul Immunol Inflamm Date: 2012-04-24 Impact factor: 3.070
Authors: Robert J Barry; Mohammad O Tallouzi; Nick Bucknall; Jonathan M Mathers; Philip I Murray; Melanie J Calvert; David J Moore; Alastair K Denniston Journal: Cochrane Database Syst Rev Date: 2018-12-18